These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24820259)

  • 1. A comparative assessment of active surveillance for localized prostate cancer in the community versus tertiary care referral center.
    Becker A; Seiler D; Kwiatkowski M; Kluth LA; Schnell D; Graefen M; Schlomm T; Fisch M; Recker F; Weissbach L; Chun FK
    World J Urol; 2014 Aug; 32(4):891-7. PubMed ID: 24820259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patterns of care of patients with localized prostate cancer in Germany: a health care study with focus on active surveillance].
    Chun FK; Becker A; Kluth LA; Seiler D; Schnell D; Fisch M; Graefen M; Weissbach L
    Urologe A; 2015 Jan; 54(1):6-13. PubMed ID: 25391440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
    Herden J; Weissbach L
    World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
    Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
    BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
    Herden J; Schwarte A; Boedefeld EA; Weissbach L
    Urol Int; 2021; 105(5-6):428-435. PubMed ID: 33517336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study.
    Herden J; Schwarte A; Werner T; Behrendt U; Heidenreich A; Weissbach L
    World J Urol; 2021 Jul; 39(7):2515-2523. PubMed ID: 33000341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study.
    Herden J; Wille S; Weissbach L
    BJU Int; 2016 Aug; 118(2):258-63. PubMed ID: 26332209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Treatment of Localized Prostate Cancer in Everyday Practice in Germany.
    Herden J; Ansmann L; Ernstmann N; Schnell D; Weißbac L
    Dtsch Arztebl Int; 2016 May; 113(19):329-36. PubMed ID: 27232362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
    Reinhold T; Dornquast C; Börgermann C; Weißbach L
    Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?
    Herden J; Heidenreich A; Weissbach L
    BJU Int; 2017 Aug; 120(2):212-218. PubMed ID: 27862832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Noninvasive treatment of organ-confined prostate cancer in elderly patients-results of the HAROW study].
    Herden J; Boedefeld EA; Weißbach L
    Urologe A; 2020 Apr; 59(4):450-460. PubMed ID: 32025749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.
    Abdel-Rahman O
    Clin Transl Oncol; 2019 Dec; 21(12):1673-1679. PubMed ID: 30929179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1117-1121. PubMed ID: 31909690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The HAROW study: an example of outcomes research: a prospective, non-interventional study comparing treatment options in localized prostate cancer].
    Herden J; Ernstmann N; Schnell D; Weißbach L
    Urologe A; 2014 Dec; 53(12):1743-52. PubMed ID: 25412911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 Decades.
    Eifler JB; Alvarez J; Koyama T; Conwill RM; Ritch CR; Hoffman KE; Resnick MJ; Penson DF; Barocas DA;
    J Urol; 2017 Mar; 197(3 Pt 1):614-620. PubMed ID: 27984110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
    Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
    JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.